This is a summary of an article that reported results of a study using data from two phase 3 clinical trials called “PALOMA-2” and “PALOMA-3.” Both PALOMA-2 and PALOMA-3 trials included women with HR+/HER2− advanced breast cancer. HR+/HER2− breast cancer means the breast cancer cells of these women have receptors for female sex hormones and little or no HER2 receptors.Both PALOMA trials tested the effect of adding a medication called palbociclib (brand name, Ibrance®) to a hormone therapy. Hormone therapy, also known as endocrine therapy, is a treatment that blocks or removes hormones that cause cancer cells to grow and divide. In both trials, women took endocrine therapy with either palbociclib or a placebo.

This Plain Language Summary of Publication article from Future Oncology reports the results of two studies called PALOMA-2 and PALOMA-3. Both studies included women with a type of breast cancer called HR+/HER2− advanced breast cancer. The studies particularly focused on the effects of adding a medication called palbociclib (brand name, Ibrance®) to a hormone therapy.

Visit the Future Medicine site using the link to read the full article.

There is also an accompanying video.

 

This summary is based on two original articles that were both published in the The New England Journal of Medicine.

Visit the New England Journal of Medicine site using the link to read the article.

Visit the New England Journal of Medicine site using the link to read the article.